Cell cycle, the process that governs cell division, consists of several distinct phases.
that is classified into 5 distinct molecular subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like and claudin-low. 7 Of these, the luminal type accounts for most breast tumors that express the estrogen receptor (ER) and/or progesterone receptor. Approximately 70% of human breast cancers present as ER-positive, a cancer cell subtype that requires estrogen for survival and growth. Endocrine therapy including tamoxifen, fulvestrant and letrozole is currently recognized as the most effective and clearly targeted form of adjuvant therapy for hormone-sensitive breast cancer. 8, 9 However, the prevalence of primary and acquired resistance severely restricts the efficacy of these agents in the clinic, 10 and the development of new treatments for breast cancer is a research priority.
First-generation CDK inhibitors were nonselective, pan-CDK blocking agents that showed limited antitumor activity and excessive toxicity. 11 More recently, increasingly potent, selective, smallmolecule CDK4/6 inhibitors, such as palbociclib, ribociclib and abemaciclib, have been developed in the setting of metastatic luminal breast cancer. 12 Clinical studies have demonstrated encouraging efficacy of combined treatment with palbociclib and fulvestrant or letrozole. 13, 14 Although evidence for the efficacy of palbociclib is compelling, daily treatment causes severe neutropenia, which necessitates a 7-day treatment "holiday". 15 Overall survival is not extended by implementation of this strategy, however, indicating that a better understanding of resistance mechanisms and further evaluation of combination strategies are needed. 16 These drugs are also usually expensive or unavailable to patients in China. Collectively, these observations highlight the desirability of developing new CDK4/6 inhibitors with improved efficacy and reduced toxicity.
SHR6390, a novel CDK4/6 inhibitor developed by the Chinese pharmaceutical company Jiangsu Hengrui Medicine (Jiangsu, China), has been shown to exhibit potent antitumor activity in esophageal squamous cell carcinoma. 17 In the current study, we performed a pharmacological characterization of SHR6390, testing it against a panel of tumor models. SHR6390 showed potent and broadspectrum antitumor activity in RB-positive cancer cell lines. In in vivo xenografts, SHR6390 exhibited favorable pharmacokinetic and pharmacodynamic properties without causing noticeable toxicity.
Importantly, SHR6390 overcame acquired resistance to tamoxifen and trastuzumab, and exerted synergistic antitumor activity in combination with endocrine therapy in breast cancers. Thus, these results provide a rationale for the ongoing clinical trials of SHR6390.
| MATERIAL S AND ME THODS

| Materials
SHR6390 and palbociclib were provided by Jiangsu Hengrui
Medicine. 4-OH tamoxifen, tamoxifen, trastuzumab, fulvestrant and letrozole were purchased from Selleckchem (Shanghai, China).
Antibodies against Ser780-phosphorylated RB (p-RB), RB, cyclin D1, p16 and tubulin were purchased from Cell Signaling Technology (Beverly, MA, USA).
| Cell lines and culture
The cell lines MCF7, ZR-75-1, T-47D, A549, SK-OV-3, NCI-H292, U-87   MG, PC-3, SNU-398, SNU-475, SNU-182, OVCAR-3, LN-18, HS-578T,   MDA-MB-231 and MV-4-11 were purchased from the American Type   Culture Collection (Manassas, VA, USA). MDA-MB-468, ES-2, SW620, COLO 205, A2780, Calu-3 and Hep G2 cell lines were purchased from Shanghai Cell Bank (Shanghai, China). The MCF7/ARO cell line was established by stably transfecting the MCF7 with human aromatase.
The tamoxifen-resistant cell line MCF7/TR was established by culturing MCF7 cells with gradually increasing concentrations of tamoxifen.
The trastuzumab-resistant cell line BT-474/T was established from the BT474 cell line as described previously. 
| Cell proliferation assay
Cells were seeded into 96-well plates and then treated with different concentrations of drugs for 6 days. Cell proliferation was evaluated using the SRB (Sigma-Aldrich, St. Louis, MO, USA) or MTT (Sigma-Aldrich) assay. 19 Drug combination studies were performed by assessing the combination index (CI) value, which defines the interaction between 2 drugs as synergistic (CI < 1), additive (CI = 1) or antagonistic (CI > 1), on the basis of the median-effect principle, calculated using CalcuSyn software (Biosoft, Cambridge, UK).
| Western blotting
Cells were lysed after treating with different concentrations of drugs. Proteins were separated and transferred as well as incubated with antibodies. Proteins were visualized using a western blot imaging System (Clinx Science Instruments, Shanghai, China).
| Cell cycle analysis
Cells were treated with drugs for 24 hours and harvested, then stained with propidium iodide (BD Biosciences, San Jose, CA, USA) and incubated. DNA content was determined using a FACS Calibur flow cytometry system (BD Biosciences). Data were analyzed using ModFit 3.0 software (BD Biosciences).
| Senescence assay (β-galactosidase staining)
According to the manufacturer's instructions of the Senescence 
| In vivo study
Animal experiments were conducted in accordance with guide- Control groups were given vehicle alone, and treatment groups received oral SHR6390, palbociclib, or SHR6390 plus tamoxifen or letrozole. Tumor volume was calculated as (length × width 2 )/2.
Pharmacokinetic/pharmacodynamic studies were carried out as described previously. 20 Concentrations of SHR6390 in plasma and tumor tissue were determined by high-pressure liquid 
| Statistical analysis
| RE SULTS
| SHR6390 inhibits the proliferation of retinoblastoma-positive tumor cell lines
On the basis of biochemical kinase assay (Table S1 ) and previously demonstrated CDK4/6 inhibitory activity of SHR6390, 17 we tested the ef- Irreversible cell cycle arrest can result in cellular senescence. 23 Next, senescence β-galactosidase staining was used to investigate whether SHR6390 could induce senescence. As show in Figure 2E at 150 mg/kg caused tumor regression, an inhibitory effect that was retained for at least 12 days after termination of SHR6390 treatment ( Figure 4C ). All of these treatments were well tolerated, as evidenced by the absence of drug-related deaths and significant body weight loss in all groups during the course of the experiment ( Figure 4A -C).
| Combined SHR6390 and endocrine therapy exerts synergistic antiproliferative effects on estrogen receptor-positive breast cancer cell lines
The combination of endocrine therapy and CDK4/6-selective inhibitors has proven to be an effective approach for improving antitumor activity against ER-positive breast cancers. 25 Here, we found that presented as means ± SEM (*P < .05, **P < .01, ***P < .001, ****P < .0001 vs vehicle)
therapy was generally well-tolerated, and no additive body weight loss was observed in any group during the course of the experiment.
| D ISCUSS I ON
Dysregulated cell cycle machinery has been identified as an essential driver of malignant behavior. The cyclin-CDK-RB pathway is an important regulator of the cell cycle; consequently, targeting this pathway is a promising strategy for treating cancers. Endocrine therapy has considerably improved survival in breast cancer patients over the past several decades. However, resistance to these therapies often develops and is a leading cause of treatment failure. 37 Several molecular mechanisms have been proposed to account for endocrine resistance, most of which center on the ER or estrogen signaling networks. [38] [39] [40] Despite the fact that mechanisms of various endocrine therapies are complicated and incompletely elucidated, there is a widely held consensus that CDK4/6 cell cycle pathways offer significant opportunities for therapeutic intervention in endocrine-resistant breast tumors. 41, 42 In agreement with this, we found that SHR6390 alone significantly inhibited RB phosphorylation and cell proliferation in the tamoxifen-resistant MCF7/TR cell line, where it exhibited the same potency as that against the parent cell line. A previous study suggested that CDK4/6 inhibitors may be effective against HER2-positive breast cancer. 43 More recently, an elegant study using a transgenic mouse model demonstrated that activation of cyclin D/CDK4 mediates resistance to HER2. 44 In the current study, we found that SHR6390 exhibited even greater potency against the trastuzumab-resistant BT-474/T cell line than against parental BT-474 cells. Our previous study showed that enhanced expression of epidermal growth factor receptor (EGFR), as well as elevated levels of p-AKT and p-ERK may be responsible for the resistance to trastuzumab in BT-474/T cells. 18 These results are compatible with those of a previous study suggesting that CDK4/6 blockade reduced TSC2 phosphorylation, leading to attenuation of mTORC1 activity, an effect that was shown to relieve feedback inhibition of EGFR family kinases and thus sensitized the respective cells to EGFR/HER2 blockade. These observations indicate that SHR6390 is a good alternative option for breast cancer, including those forms that are resistant to endocrine and anti-HER2 therapies.
Our preclinical results suggest that SHR6390 exerts its antitumor activity mainly through specific effects on RB and, thus, Selective CDK4/6 inhibitors together with other targeted agents or chemotherapy are also being investigated in the setting of advanced cancers. 13, 14 Although combination therapy has yielded better results in clinical studies performed to date, identifying the most promising and best-tolerated CDK4/6 inhibitor combination therapies is a significant challenge. 46, 47 In this context, the combina- 
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